Can NF-κB Be Considered a Valid Drug Target in Neoplastic Diseases? Our Point of View

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)


Multidrug resistance (MDR), of the innate and acquired types, is one of major problems in treating tumor diseases with a good chance of success. In this review, we examine the key role of nuclear factor-kappa B (NF-κB) to induce MDR in three tumor models characterized precisely by innate or acquired MDR, in particular triple negative breast cancer (TNBC), hepatocellular carcinoma (HCC), and acute myeloid leukemia (AML). We also present different pharmacological approaches that our group have employed to reduce the expression/activation of this transcriptional factor and thus to restore chemo-sensitivity. Finally, we examine the latest scientific evidence found by other groups, the most significant clinical trials regarding NF-κB, and new perspectives on the possibility to consider this transcriptional factor a valid drug target in neoplastic diseases.
Original languageEnglish
Pages (from-to)1-20
Number of pages20
JournalInternational Journal of Molecular Sciences
Publication statusPublished - 2020

All Science Journal Classification (ASJC) codes

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry


Dive into the research topics of 'Can NF-κB Be Considered a Valid Drug Target in Neoplastic Diseases? Our Point of View'. Together they form a unique fingerprint.

Cite this